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Abstract
Influenza A virus infection is a common respiratory tract infection. Alveolar
hemorrhage has been reported in patients with influenza pneumonia and in
mice infected with influenza A. In this study, we investigated the effect of two
anticoagulants on alveolar hemorrhage after influenza A virus (IAV) infection
of wild-type mice. Wild-type mice were anticoagulated with either warfarin or
the direct thrombin inhibitor dabigatran etexilate and then infected with a
mouse-adapted influenza virus (A/Puerto Rico/8/34 H1N1). Alveolar hemor-
rhage was assessed by measuring hemoglobin levels in the bronchoalveolar
lavage fluid (BALF). We also measured vascular permeability and viral gen-
omes in the lung, as well as white blood cells, inflammatory mediators, and
protein in BALF. Survival and body weight were monitored for 14 days after
influenza A infection. In infected mice receiving either warfarin or dabigatran
etexilate we observed decreased activation of coagulation in the BALF and
increased alveolar hemorrhage. Warfarin but not dabigatran etexilate increased
vascular permeability and mortality of influenza A-infected mice. Anticoagula-
tion did not affect levels of influenza A genomes, white blood cells, inflamma-
tory mediators, or protein in the BALF. Our study indicates that systemic
anticoagulation increases alveolar hemorrhage in influenza A-infected mice.
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
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Introduction
Influenza, also known as the flu, causes considerable mor-
bidity and mortality worldwide every year especially in
elderly people. One of the viruses causing this infectious
disease is the influenza A virus (IAV), which infects the
respiratory tract, resulting in bronchitis, pneumonia, and
acute respiratory distress syndrome (Bramley et al. 2012;
Zhang et al. 2012). There is a high mortality associated
with IAV infection especially when the disease is associ-
ated with the H1N1 strain of virus (Bramley et al. 2012).
In general, viral infections are associated with activation
of coagulation and in some cases, such as Ebola, this may
result in hemorrhagic fever (Geisbert et al. 2003; Antoniak
et al. 2008, 2013; Huerta-Zepeda et al. 2008; Funderburg
et al. 2010; Goeijenbier et al. 2012; Antoniak and Mack-
man 2014). Indeed, patients with acute IAV infection exhi-
bit a high incidence of cardiovascular events, including
myocardial infarction and stroke (Smeeth et al. 2004). We
and others reported that IAV infection activates the coagu-
lation system in the airspace (Zhang et al. 2012; Antoniak
et al. 2016b). Despite this local activation of coagulation,
alveolar hemorrhages are observed in mice infected with
IAV and also in patients with influenza pneumonia (Gilbert
et al. 2010; Zhang et al. 2012; von Ranke et al. 2013; Anto-
niak et al. 2016b). We recently reported that expression of
the procoagulant protein tissue factor (TF) in lung epithe-
lial cells maintains lung hemostasis after IAV infection
(Antoniak et al. 2016b).
Anticoagulants are widely prescribed drugs that are
used to prevent or treat venous thromboembolism (VTE),
and to prevent stroke in patients with atrial fibrillation
and mechanical prosthetic heart valves (Thaler et al.
2015). Vitamin K antagonists (VKAs), such as warfarin,
are the most commonly used oral anticoagulant drugs.
They exert their anticoagulant effect by suppressing the
gamma-carboxylation of the vitamin K-dependent proco-
agulant factors prothrombin, factor VII, factor IX, and
factor X (Witt et al. 2016), as well as anticoagulant fac-
tors protein C and protein S. Although VKAs are highly
effective, they have a narrow therapeutic range, interact
with food and other drugs, require regular monitoring,
and need frequent dose adjustments. More recently a new
class of oral anticoagulants, the direct-acting oral antico-
agulants (DOACs), has been introduced for clinical use as
an alternative to warfarin and other VKAs (Burnett et al.
2016). Dabigatran etexilate (DE) directly inhibits throm-
bin, whereas rivaxobaban, apixaban, and edoxaban all
inhibit factor Xa. Their pharmacological profile is charac-
terized by a rapid onset of action, a relatively short half-
life, less drug or food interactions, and they can be used
in fixed doses without the need of routine monitoring.
In this study, we hypothesized that mice treated with anti-
coagulants would have increased alveolar hemorrhage after
IAV infection. We investigated the effect of two different
anticoagulants, warfarin and DE, on alveolar hemorrhage
and survival in wild-type (WT) mice after IAV infection.
Material and Methods
Mice
We used 8- to 10-week-old male WT (C57Bl/6J) mice for
all experiments. All experimental protocols were approved
by the University of North Carolina-Chapel Hill’s Institu-
tional Animal Care and Use Committee.
Influenza A virus
A mouse-adapted strain of influenza A/Puerto Rico/8/
1934 (H1N1, PR/8) (ATCC, Manassas, VA) was propa-
gated in 10- to 12-day-old embryonated chicken eggs and
the virus was purified as described (Antoniak et al. 2013).
A hemagglutination assay was used to measure viral titers
(Antoniak et al. 2013).
Infection of mice with influenza A and
outcome measures
We infected mice intranasally with a dose of 0.02 hemag-
glutination units (HAU) in 50 lL phosphate-buffered sal-
ine (PBS) (Antoniak et al. 2013, 2016b). After IAV
infection, survival and body weights were analyzed up to
14 days. As per our animal protocol, mice with a ≥ 25%
loss of initial body weight were euthanized. Lungs and
bronchoalveolar lavage fluid (BALF) samples were col-
lected 7 days after infection.
Anticoagulation of mice
WT mice were given either 2 or 4 lg/mL of warfarin
(Sigma-Aldrich, St. Louis, MO) via drinking water for
3 days and then infected with IAV. Water was refreshed
every other day. For inhibition of thrombin, mice were
fed a chow containing DE (10 mg/g chow) as described
(Antoniak et al. 2016, 2013).
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Coagulation parameters
For measuring the prothrombin time (PT), 50 lL of PT
reagent containing calcium chloride (Thromboplastin-D,
Pacific Hemostasis, Middletown, VA) was added to
25 lL of plasma. For measuring the activated partial
thromboplastin time (aPTT), 25 lL of aPTT reagent
(TriniCLOT aPTT S, Tcoag, Wicklow, Ireland) was
mixed with 25 lL of plasma and 25 lL of 0.025mol/L
calcium chloride. Clotting times were measured using a
STart4 coagulation analyzer (Diagnostica Stago, Parsip-
pany, NJ). Bleeding times were measured by saphenous
vein injury model as described (Monroe and Hoffman
2014), and represented as an average hemostasis time
after clot disruptions. Levels of thrombin-antithrombin
complexes (TATc) in BALF supernatant were quantified
by ELISA (TAT Enzygnost Micro Kit; Dade Behring,
Deerfield, IL).
Bronchoalveolar lavage
After euthanizing the mice, BALF was collected using
3 9 900 lL of ice-cold PBS. Cells were isolated from
the BALF by centrifugation (500 9 g, 20 min, 4°C)
(Antoniak et al. 2013, 2016b). The cells were resus-
pended in 200 lL of ice-cold PBS. Levels of white
blood cells (WBC) and hemoglobin in the resuspended
cell pellet samples were determined using a Hemavet
950 (Drew Scientific, Miami Lakes, FL). Protein and
albumin concentrations in BALF was quantified with
the RC DC™ Protein Assay (Bio-Rad Laboratories,
Hercules, CA) and the Mouse Albumin ELISA Quanti-
tation Set (Bethyl Laboratories, Montgomery, TX),
respectively.
RNA isolation and RT-PCR
Total lung RNA was extracted using TRIzol (Life Tech-
nologies, Carlsbad, CA). RNA was reverse transcribed into
cDNA using the iScript™ RT Supermix (Bio-Rad) and the
levels of H1N1 PR/8 genomes were quantified by real-
time PCR using SSoFast™ Probes Supermix and a Bio-
Rad cycler (Bio-Rad) as described (Antoniak et al. 2016,
2013, 2016a,b). Rpl4 was used for normalization. Real-
time PCR primer/probes were purchased from Integrated
DNA Technologies (Coralville, IA).
Measurement of cytokines/chemokines
The levels of mouse IL-1b, Ccl2 (MCP-1), Ccl5
(RANTES), and Cxcl10 (IP-10) in the BALF supernatants
were measured using commercially available ELISA kits
(Duo-Set, R&D Systems, Minneapolis, MN).
Vascular Permeability
Vascular permeability in the lung after IAV infection was
analyzed using the Evans Blue method (Sparkenbaugh et al.
2015). Mice were retroorbital injected with 100 lL of 1%
Evans Blue solution (Sigma-Aldrich). One hour later, mice
were anesthetized and the lung was perfused with PBS
through the right heart ventricle. The whole lung was col-
lected and dried for 2 days at 55°C. Dry lung tissue was
minced and incubated at 37°C for 2 days with formamide
(1 mL/ 100 mg lung weight, Sigma-Aldrich) to extract the
Evans Blue. The concentration of Evans Blue was calculated
from absorbance readings at 620 nm of the cleared for-
mamide supernatant. Differences in Evans Blue injection
efficiency was normalized to Evans Blue concentrations in
the plasma.
Statistics
GraphPad Prism (version 5.0; GraphPad Software Inc., La
Jolla, CA) was used for all statistical analyses. Data are
represented as mean  standard error of the mean. For
two-group comparison of continuous data, two-tailed
Student’s t-test was used. For multiple-group comparison,
data were analyzed by one- or two-way ANOVA and were
Bonferroni corrected for repeated measures over time.
Survival rates were analyzed by Kaplan–Meier analysis
and the log-rank test was applied to compare the survival
distribution between groups. A P value less than 0.05 was
considered statistically significant.
Results
Anticoagulation of mice with warfarin or DE
Mice were anticoagulated with either warfarin or DE. We
used two different doses of warfarin administered via the
drinking water and one dose of DE administered via the
chow. Warfarin significantly increased the PT in a dose-
dependent manner compared with untreated mice (Fig. 1A
and B). Administration of DE significantly increased the
aPTT compared with untreated mice (Fig. 1C). In addi-
tion, the high dose of warfarin and DE also significantly
increased saphenous vein bleeding compared with controls
(Fig. 1D). These results indicate that mice were signifi-
cantly anticoagulated using both types of anticoagulants.
Effect of warfarin and DE on activation of
coagulation and alveolar hemorrhage in
mice after influenza A virus infection
As expected from recent studies (Keller et al. 2006; Anto-
niak et al. 2016b), IAV infection of mice increased levels
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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of TATc in the BALF indicating activation of coagulation
(Fig. 1E and F). However, TATc levels were significantly
lower in mice receiving either the high dose of warfarin
or DE (Fig. 1E and F). The low dose of warfarin also
reduced levels of TATc, but this decrease was not statisti-
cally significant (Fig. 1E). These results indicate that anti-
coagulation reduces the activation of coagulation in the
lungs of WT mice after IAV infection.
We and others have reported alveolar hemorrhage in
mice after IAV infection (Keller et al. 2006; Schouten
et al. 2010a,b; Antoniak et al. 2016b). As expected, IAV
infection of WT mice led to a low level of alveolar hem-
orrhage (Fig. 2A and B). We observed a significant
increase in alveolar hemorrhage in IAV-infected mice
receiving a high dose of warfarin or DE (Fig. 2A and B).
The low dose of warfarin increased alveolar hemorrhage,
but this was not statistically significant (Fig. 2B). War-
farin or DE did not increase the alveolar hemorrhage in
uninfected mice (Fig. 2A). These results indicate that
administration of anticoagulants to mice decreases activa-
tion of coagulation and increases alveolar hemorrhage
after IAV infection.
Effect of warfarin or DE on morbidity and
mortality of mice after influenza A virus
infection
IAV infection alone led to a decrease in body weight of
10–19% of the mice at 9 days after infection and beyond
(Fig. 3A, C, and E, black lines). We observed a low num-
ber of deaths in mice receiving warfarin alone (1 of 24
mice [4%] with the 2 lg/mL dose of warfarin, and 3 of
13 mice [23%] with the 4 lg/mL dose of warfarin)
(Fig. 3A and C, blue lines). Two of the four mice that
died with warfarin alone were examined post mortem;
one had a subcutaneous bleed and one had both subcuta-
neous and gastrointestinal bleeds. Mice treated with the
low dose of warfarin (2 lg/mL) exhibited a trend toward
increased mortality after IAV infection (3 died of 7 mice,
43%) (P = 0.17), but all of these mice were euthanized
due to a reduction in body weight (Fig. 3A, red line).
IAV-infected mice treated with the high dose of warfarin
(4 lg/mL) exhibited a significantly higher mortality (8
died of 17 mice, 48%) compared with IAV-infected con-
trols (P < 0.05) (Fig. 3C, red line). Of the eight dead
Figure 1. Anticoagulating mice with warfarin or dabigatran etexilate. Wild-type (WT) mice were untreated or treated with 2 or 4 lg/mL of
warfarin via drinking water for 3 (A) or 7 (B) days and the level of anticoagulation was assessed by measuring the prothrombin time (PT). (C)
WT mice were untreated or treated with dabigatran etexilate (DE) containing chow (10 mg/g of chow) for 3 days and the level of
anticoagulation was assessed by measuring the activated partial thromboplastin time (aPTT). (D) Bleeding times of untreated WT mice or mice-
receiving warfarin (4 lg/mL, drinking water) or DE (10 mg/g of chow) for 3 days were determined using the saphenous vein injury model. Data
are represented as an average hemostasis time after clot disruptions. WT mice were untreated or treated with warfarin via drinking water (2 or
4 lg/mL) or DE via chow (10 mg/g of chow) for 3 days before being infected with influenza A virus (IAV) intranasally. (E) Levels of thrombin–
antithrombin complexes (TATc) in bronchoalveolar lavage fluid (BALF) of control (C; white), and 2 lg/mL (W2; light gray) or 4 lg/mL (W4; dark
gray) of warfarin-treated mice before and 7 days after IAV infection. (F) Levels of TATc in BALF of control (white) or DE-fed (black) mice 7 days
after IAV infection. Data were analyzed by one-way ANOVA for A, B, and D, and Student’s t-test for C. Data are represented as mean, and
statistical significances are indicated as * (P < 0.05), ** (P < 0.01), and *** (P < 0.001) between groups. The numbers of mice used are as
follows: 11, 10, and 5 for A; 10, 3, and 10 for B; 9 and 9 for C; and 4, 5, and 4 for D. Data were analyzed by two-way ANOVA for E, and by
Student’s t-test for F. Data are represented as mean  SEM, and statistical significances are indicated as * (P < 0.05) and *** (P < 0.001)
between groups, or ## (P < 0.01) and ### (P < 0.001) versus uninfected control of the respective group. The numbers of mice used are as
follows: uninfected (8, 8, and 8), infected (7, 8, and 13) for E, and 5 and 5 for F.
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mice three were found dead between days 3 and 8. Two
of the three mice that died early were examined post
mortem; one had a gastrointestinal bleed and one had a
lung bleed. The remaining five mice had a decrease in
body weight between days 9 and 11. Interestingly, both
the low and high doses of warfarin treatment accelerated
the recovery of body weight compared with control mice
after IAV infection (Fig. 3B and D). Administration of
DE did not cause any spontaneous death and did not
increase the number of mice that were euthanized due to
a reduction in body weight after IAV infection (Fig. 3E).
In addition. DE did not affect the weight loss and recov-
ery of IAV-infected mice (Fig. 3F). These results indicate
that only a high dose of warfarin increases early death of
mice after IAV infection, whereas both doses of warfarin
affected the recovery of body weight. DE did not affect
mortality or weight gain in IAV-infected mice.
Effect of warfarin and DE on vascular
permeability in the lung after influenza A
infection
Warfarin but not DE reduces levels of factor VII and pro-
tein C and this may affect vascular permeability by reduc-
ing barrier protection via protease-activated receptor 1 in
the endothelium (Sen et al. 2011). Consistent with this
hypothesis, we observed a significant increase in vascular
permeability when IAV-infected mice were treated with
warfarin but not DE compared with IAV infection alone
(Fig. 4). Importantly, anticoagulation alone had no effect
on vascular permeability within the lung (Fig. 4).
Anticoagulation does not affect viral
genomes or inflammation
Recently we found that maximal levels of IAV genomes
and inflammatory mediators were observed 7 days after
IAV infection of mice (Antoniak et al. 2016b). Therefore,
we determined if administration of anticoagulants was
associated with changes in IAV genomes 7 days after
infection. Anticoagulation did not change the levels of
IAV genome in the lungs of the infected mice (Fig. 5A).
In addition, there were no differences in the levels of total
protein or albumin in the BALF of infected mice treated
with the two anticoagulants (Fig. 5B and C).
Previous studies have reported crosstalk between coag-
ulation and inflammation (Antoniak et al.2016, 2013,
2016a; Andrade et al. 2013; Wilson et al. 2014; Azeredo
et al. 2015; Yang and Tang 2016). Therefore, we deter-
mined if anticoagulation affected the recruitment of
Figure 2. Anticoagulation with warfarin or dabigatran etexilate increases alveolar hemorrhage in mice after influenza A infection. Wild-type
mice were untreated or treated with warfarin via the drinking water (2 or 4 lg/mL) or dabigatran etexilate (DE) via chow (10 mg/g of chow)
for 3 days and were infected with influenza A virus (IAV) intranasally. (A) (Left) Gross appearance of bronchoalveolar lavage fluid (BALF) from
three representative mice receiving with warfarin before and 7 days after IAV infection. (Right) Levels of hemoglobin (Hb) in BALF of control
mice (C; white), and 2 lg/mL (W2; light gray) or 4 lg/mL (W4; dark gray) of warfarin-treated mice before and 7 days after IAV infection. (B)
(Left) Gross appearance of BALF from three representative mice with or without DE chow 7 days after IAV infection. (Right) Levels of Hb in
BALF of control (white) or DE-fed (black) mice at 7 days after IAV infection. Data were analyzed by two-way ANOVA for A, and by Student’s
t-test for B. Data are represented as mean  SEM, and statistical significances are indicated as * (P < 0.05) between groups, or ## (P < 0.01)
versus uninfected control of the respective group. The numbers of mice used are as follows: uninfected (8, 8, and 8), infected (7, 9, and 14)
for A, and 4 and 5 for B.
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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WBCs and inflammatory mediators in the BALF in IAV-
infected mice. The number of WBC or cytokines/
chemokines levels in the BALF 7 days postinfection did
not differ in mice treated with either warfarin or DE
(Fig. 6A–C).
Discussion
In this study, we found that administration of two differ-
ent anticoagulants to mice infected with influenza A led
to a significant increase in alveolar hemorrhage. The
doses of warfarin that we used are similar to the thera-
peutic dose used in patients (Foerch et al. 2008). We
observed a significant increase in mortality (48%) in
IAV-infected mice receiving a high dose of warfarin com-
pared with IAV-infected alone (19%) or warfarin alone
(23%). In contrast, administration of DE did not increase
mortality of IAV-infected mice. Interpretation of the
mortality data is complicated by the fact that warfarin
alone caused death of some mice. Death due to bleeding
was observed between 3 and 8 days after infection,
whereas “death” due to weight loss was observed 9 days
Figure 3. Effect of anticoagulation on morbidity and mortality in mice after influenza A infection. Wild-type mice were untreated or treated
with low- (2 lg/mL; W2) (A and B) and high- (4 lg/mL; W4) (C and D) dose warfarin via drinking water, or dabigatran etexilate (DE) via chow
(10 mg/g of chow; DE) (E and F) for 3 days and were infected with influenza A virus (IAV) intranasally. The different groups are designated
with different colors: blue indicates mice receiving anticoagulants alone; black indicates IAV alone; and red indicates mice that received
anticoagulation and were infected. Body weights before infection were set to 100%. Survival (mean  SEM; n = 7–27 per group) and body
weight data were analyzed by log-rank test (A, C, and E), or by two-way ANOVA (B, D, and F). Statistical significance is indicated as
* (P < 0.05) between IAV-infected mice with and without anticoagulants.
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postinfection and beyond. Why do we observe an
increase in death with warfarin but not with DE? One
possibility is that the high dose of warfarin is producing
a higher level of anticoagulation than the dose of DE. A
recent study evaluated the effect of warfarin and DE in
two mouse models of intracerebral hemorrhage (Lauer
et al. 2011). The study reported that warfarin increased
hemorrhage, whereas DE did not increase hemorrhage.
The authors suggested that the incidence of microhemor-
rhages with warfarin- and DE-treated mice is similar but
that with warfarin these hemorrhages are more likely to
progress to major bleedings (Lauer et al. 2011). Clinical
studies have reported higher levels of major bleeding in
patients treated with warfarin compared with DE (Hori
et al. 2013; Salazar et al. 2014) and the use of DOACs in
patients with atrial fibrillation is associated with less
intracranial hemorrhage compared to warfarin (Ruff et al.
2014).
In our study, the high dose of warfarin and DE pro-
duced similar bleeding in a saphenous vein model, and a
similar reduction in TATc in the BALF of IAV-infected
mice. In addition, levels of alveolar hemorrhage in IAV-
infected mice were increased to a similar extent with
both anticoagulants. These results suggest that the levels
Figure 4. Effect of anticoagulation on vascular permeability after
influenza A infection. Wild-type mice were untreated or treated
with high- (4 lg/mL; W4) dose warfarin via drinking water, or
dabigatran etexilate (DE) via chow (10 mg/g of chow) for 3 days
and were infected with influenza A virus (IAV) intranasally for
3 days. Mice treated with warfarin (W4) or DE without IAV
infection were used as controls. Vascular permeability was
determined by measuring levels of Evans blue in the lungs. Data
were analyzed by one-way ANOVA. Statistical significance is
indicated as * (P < 0.05) between IAV-infected mice with and
without anticoagulants.
Figure 5. Effect of anticoagulation on IAV genomes and protein in the bronchoalveolar lavage fluid. Wild-type mice were untreated or treated
with low (2 lg/mL; W2) and high (4 lg/mL; W4) doses of warfarin or dabigatran etexilate (DE) for 3 days before influenza A infection. (A)
Levels of influenza A genomes in the lungs were measured in control and anticoagulated mice 7 days after infection. Levels of total protein (B)
and albumin (C) in the bronchoalveolar lavage fluid in control and anticoagulated mice 7 days after infection.
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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of anticoagulation are comparable with the two anticoag-
ulants. Warfarin and DE did not affect levels of viral
genomes in the lung and levels of WBC, inflammatory
mediators, or protein in the BALF. Therefore, an alterna-
tive possibility is that warfarin is affecting molecules or
pathways that are not affected by DE. Importantly, war-
farin treatment leads to unselective reduction in the vita-
min K-dependent procoagulant factors prothrombin, VII,
IX, X, and the anticoagulant factors protein C and S,
whereas DE only inhibits thrombin activity. Protein C
and factor VII have been shown to mediate vascular pro-
tection via the endothelial protein C receptor and pro-
tease-activated receptor-1 in certain disease models, such
as stroke and endotoxemia (Sen et al. 2011; Zlokovic
and Griffin 2011). Indeed, we found that warfarin but
not DE significantly increased vascular permeability in
the lung after IAV infection compared to IAV alone.
Interestingly, administration of warfarin significantly
increased the body weight recovery beyond 9 days with
the high dose and beyond 10 days with the low dose.
Currently, we do not know how warfarin is affecting
body weight.
In summary, we demonstrate a critical protective role
for the coagulation cascade in the lung in a model of sev-
ere influenza pneumonia. Although alveolar hemorrhage
is a well-described feature of influenza pneumonia, stud-
ies on the impact of anticoagulant therapy on the severity
of illness and outcomes from influenza are lacking. Our
results suggest that chronic anticoagulation with warfarin
or other anticoagulants, such as DE, could contribute to
more severe alveolar hemorrhage in the setting of influ-
enza pneumonia.
Figure 6. Effect of anticoagulation on white blood cell counts and inflammatory mediators in the bronchoalveolar lavage fluid. Wild-type mice
were untreated or treated with low (2 lg/mL; W2) and high (4 lg/mL; W4) doses of warfarin or dabigatran etexilate (DE) for 3 days before
influenza A infection. Levels of white blood cells (WBC) and various cytokines/chemokines in the bronchoalveolar lavage fluid (BALF) were
measured 7 days after influenza A infection. (Panel A) shows levels of WBC in the different groups. (Panels B and C) show the effect of
warfarin and DE on levels of cytokines/chemokines in mice treated with high-dose warfarin or DE, respectively. Data (mean  SEM; n = 4–17
per group) were analyzed by Student’s t-test.
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